#cancer
cancer
7,201 views
57 Discussing
Hot
Latest
🚨 MODERNA’S mRNA CANCER BREAKTHROUGH
Moderna ($MRNA) is making headlines after its personalized mRNA cancer vaccine, developed with Merck, delivered positive Phase 3 results in melanoma patients.
The treatment, intismeran, is designed around each patient’s specific tumor mutations and is used alongside Merck’s Keytruda. The trial showed a significant reduction in the risk of melanoma returning or spreading compared with Keytruda alone.
The market reacted aggressively — Moderna shares more than doubled on August 19, adding roughly $30 billion in market value as investors reassessed the company’s future beyond COVID vaccines.
🔥 Why it matters: This could be a major validation of mRNA technology beyond infectious diseases, with Moderna and Merck already testing the approach across other cancers.
If further trials confirm the results and regulators approve the treatment, Moderna could be entering a completely new chapter in oncology.
$MRNA.US is no longer just a COVID vaccine story.
#MRNA #Cancer #mRNA #Biotech #StockMarket #Healthcare
Moderna ($MRNA) is making headlines after its personalized mRNA cancer vaccine, developed with Merck, delivered positive Phase 3 results in melanoma patients.
The treatment, intismeran, is designed around each patient’s specific tumor mutations and is used alongside Merck’s Keytruda. The trial showed a significant reduction in the risk of melanoma returning or spreading compared with Keytruda alone.
The market reacted aggressively — Moderna shares more than doubled on August 19, adding roughly $30 billion in market value as investors reassessed the company’s future beyond COVID vaccines.
🔥 Why it matters: This could be a major validation of mRNA technology beyond infectious diseases, with Moderna and Merck already testing the approach across other cancers.
If further trials confirm the results and regulators approve the treatment, Moderna could be entering a completely new chapter in oncology.
$MRNA.US is no longer just a COVID vaccine story.
#MRNA #Cancer #mRNA #Biotech #StockMarket #Healthcare
MRNAUS-17.26%
Verified
🚨 BREAKING: Moderna $MRNA JUST EXPLODED 130%!
Its personalized mRNA cancer vaccine, developed with Merck, delivered a HISTORIC Phase 3 win in high-risk melanoma.
The treatment met its main goal of reducing cancer recurrence AND its secondary goal of reducing the risk of the cancer spreading.
The trial included 1,137 patients and tested Moderna’s Intismeran alongside Merck’s Keytruda.
This is the FIRST positive Phase 3 result for an mRNA cancer vaccine.
Moderna may have just opened the door to an entirely new era of personalized cancer treatment.
The full data is still to come, but Wall Street is already pricing in massive potential for the technology beyond melanoma.
#Moderna #MRNA #Cancer #Biotech #Stocks $MRNA.US
Its personalized mRNA cancer vaccine, developed with Merck, delivered a HISTORIC Phase 3 win in high-risk melanoma.
The treatment met its main goal of reducing cancer recurrence AND its secondary goal of reducing the risk of the cancer spreading.
The trial included 1,137 patients and tested Moderna’s Intismeran alongside Merck’s Keytruda.
This is the FIRST positive Phase 3 result for an mRNA cancer vaccine.
Moderna may have just opened the door to an entirely new era of personalized cancer treatment.
The full data is still to come, but Wall Street is already pricing in massive potential for the technology beyond melanoma.
#Moderna #MRNA #Cancer #Biotech #Stocks $MRNA.US
MRNAUS-17.26%
🚨 Our manager and Merck announce major progress in a personalized cancer vaccine using mRNA technology
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
#MichaelSaylor暗示增持BTC #CANCER
Hold onto Cancer with confidence, let's journey together over time.
Instead of blindly chasing after a hundred shitcoins, it's better to focus deeply on one quality asset.
Build a strong community, stay true to your roots, patiently position yourself, and wait for long-term gains!
Hold onto Cancer with confidence, let's journey together over time.
Instead of blindly chasing after a hundred shitcoins, it's better to focus deeply on one quality asset.
Build a strong community, stay true to your roots, patiently position yourself, and wait for long-term gains!
Layer upon layer of mountains, wrapped in swirling mist, looks like the market’s ups and downs—each a formidable test;
Sunlight pours down from above, stretching across the heavens and earth—hope and dawn for those who hold steadfast.
Five people stand shoulder to shoulder atop the mountain, symbolizing CANCER’s countless partners joining hearts and minds to stand by one another, undaunted by turbulence, and committing to long-term cultivation.
After enduring the darkness before dawn, we will gather a unified consensus among all members; in the end, we will be bathed in countless rays of light, and set out for our great future ahead.#2026足球风潮 #Cancer
Sunlight pours down from above, stretching across the heavens and earth—hope and dawn for those who hold steadfast.
Five people stand shoulder to shoulder atop the mountain, symbolizing CANCER’s countless partners joining hearts and minds to stand by one another, undaunted by turbulence, and committing to long-term cultivation.
After enduring the darkness before dawn, we will gather a unified consensus among all members; in the end, we will be bathed in countless rays of light, and set out for our great future ahead.#2026足球风潮 #Cancer
#CANCER Pink cancer cells, only the real deal shines through in the waves, what conquers the market isn’t the quick profits, but long-term stability!
Log in to explore more content